TLSI Share Price Performance
US$4.75
-0.83 (-14.87%)
58.7% undervalued intrinsic discount
US$11.50
Fair Value
Price US$4.75
AnalystConsensusTarget US$11.50
AnalystLowTarget US$9.00
AnalystHighTarget US$15.81
Fair ValueUS$11.50
Share Pricen/a
TriSalus Life Sciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
TLSI Community Narratives
AN
Fair Value US$11.5 58.7% undervalued intrinsic discount
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$9 47.2% undervalued intrinsic discount
Future Procedure Volume Risks May Limit Drug Delivery Adoption Yet Long-Term Tailwinds Remain
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$15.81 70.0% undervalued intrinsic discount
Pressure Enabled Drug Delivery Expansion Will Transform Long Term Prospects For This Undervalued Medtech
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$11.5
58.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
40.23% p.a.
Profit Margin
11.49%
Future PE
68.24x
Price in 2029
US$7.92
Pressure Enabled Drug Delivery Expansion Will Transform Long Term Prospects For This Undervalued Medtech
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops pressure enabled drug delivery devices designed to improve the performance of embolization and drug delivery procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15.81
70.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
45.36% p.a.
Profit Margin
35.69%
Future PE
27.04x
Price in 2029
US$10.86
Future Procedure Volume Risks May Limit Drug Delivery Adoption Yet Long-Term Tailwinds Remain
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops pressure enabled drug delivery technologies and specialized infusion systems to improve the treatment of solid tumors and other vascular driven conditions. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
47.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
42.09% p.a.
Profit Margin
16.03%
Future PE
36.71x
Price in 2028
US$6.18
Trending Discussion
Recently Updated Narratives
AN
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Fair Value: US$11.5 58.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pressure Enabled Drug Delivery Expansion Will Transform Long Term Prospects For This Undervalued Medtech
Fair Value: US$15.81 70.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Procedure Volume Risks May Limit Drug Delivery Adoption Yet Long-Term Tailwinds Remain
Fair Value: US$9 47.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
TriSalus Life Sciences, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.42
- 84.04%
- -176.16%
- -122.6%
About TLSI
- Founded
- 2009
- Employees
- 110
- CEO
- WebsiteView website
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
